{
    "clinical_study": {
        "@rank": "88869", 
        "arm_group": [
            {
                "arm_group_label": "Sibling Controls", 
                "description": "Healthy siblings of acute lymphoblastic leukemia (ALL) subjects frequency matched by age and sex."
            }, 
            {
                "arm_group_label": "Acute Lymphoblastic Leukemia Survivors", 
                "description": "Survivors of acute lymphoblastic leukemia (ALL) who recently completed therapy."
            }
        ], 
        "biospec_descr": {
            "textblock": "Fasting blood samples will be obtained for lipids (total cholesterol, triglycerides, LDL-\n      cholesterol, HDL-cholesterol) insulin, glucose, inflammatory cytokines (CRP, IL-6, oxidized\n      LDL), leptin, adiponectin, insulin-like growth factor 1 (IGF-1), thyroid, and gonadal\n      function."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is a prospective cohort study assessing measures of cardiometabolic status, body\n      composition, IR and GH response to stimulation after therapy in children (age 7-21 years)\n      treated for ALL. Patients and sibling controls will be recruited from the Pediatric\n      Hematology-Oncology Clinic at the University of Minnesota Amplatz Children's Hospital."
        }, 
        "brief_title": "Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia", 
        "condition": "Acute Lymphoblastic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective cohort study with two groups:  survivors of acute lymphoblastic\n      leukemia (ALL) who have recently completed therapy (cases) and healthy siblings (controls)\n      frequency matched by age and sex.  Subjects in each group will have two visits.  For cases,\n      the first visit will be approximately 6 months after completion of treatment for ALL;  for\n      their siblings, the first visit occur at approximately the same time.  For both cases and\n      controls, the second visit will be 2 to 2.5 years after the first visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients\n\n               -  Age 7 years to less than or equal to 21 years at time of study enrollment.\n\n               -  Acute lymphoblastic leukemia (ALL) as first cancer diagnosis and in first\n                  complete remission. Any subtype is eligible.\n\n               -  Study enrollment must take place at/after six months of completion of all\n                  chemotherapy.\n\n               -  Patients must have a performance status corresponding to Eastern Cooperative\n                  Oncology Group (ECOG) scores of 0, 1, or 2. Use Karnofsky for patients > 16\n                  years of age and Lansky for patients \u2264 16 years of age.\n\n               -  Any prior ALL therapy is allowable.\n\n          -  Siblings\n\n               -  Age 7 years to less than or equal to 21 years at time of study enrollment.\n\n               -  Sibling of ALL patient.\n\n        Exclusion Criteria:\n\n          -  Patients\n\n               -  Diagnosis of diabetes mellitus prior to ALL diagnosis or at time of study\n                  enrollment.\n\n               -  Current pregnancy\n\n               -  Prior hematopoietic cell transplant.\n\n               -  Receiving growth hormone replacement or corticosteroids at the time of\n                  enrollment.\n\n          -  Siblings\n\n               -  Previously diagnosed with malignancy.\n\n               -  Diagnosis of diabetes mellitus.\n\n               -  Current pregnancy\n\n               -  Receiving growth hormone replacement or corticosteroids at the time of\n                  enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "21 Years", 
            "minimum_age": "7 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Study entry is open to patients regardless of gender or ethnic background. While there\n        will be every effort to seek out and include females and minority patients, the patient\n        population is expected to be no different than the general pediatric oncology population\n        seen at the participating institutions."
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688752", 
            "org_study_id": "2012NTLS086"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 17, 2013", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia, A Pilot Study", 
        "overall_official": {
            "affiliation": "Masonic Cancer Center, University of Minnesota", 
            "last_name": "Julia Steinberger, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_outcome": {
            "description": "To determine the cardiometabolic profile (as measured by a single score based on adiposity, serum lipids, and vascular function) shortly after therapy (6 months after completion of therapy [Visit 1]) and again 2.5-3 yrs after completion of therapy (Visit 2) in 300 ALL patients, and compare with 200 sibling controls.", 
            "measure": "Cardiometabolic Profile", 
            "safety_issue": "No", 
            "time_frame": "up to  2.5-3 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688752"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To determine the prevalence of blunted stimulated GH response suggesting GH deficiency (peak GH <7mcg/L) in ALL survivors and controls: GH level will be obtained at baseline, then +30, +60, +90 and +120 minutes after clonidine (5 mcg/kg up to 200 mcg by mouth), followed by infusion of arginine (0.5 grams/kg up to 30 grams) with a series of GH levels at +140, +160, +180, +210, and +240 minutes.  Blunted response to GH stimulation will be defined as peak GH level<7 mcg/L.", 
            "measure": "Prevalence of Blunted Stimulated Growth Hormone Response", 
            "safety_issue": "No", 
            "time_frame": "Between 2.5 and 3 Years"
        }, 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013", 
        "why_stopped": "Funding unavailable"
    }
}